Gilead 4Q 4Q Revenues: $2.0 billion (+42%) 4Q Earnings: $802.2 million (+43%) FY Revenues: $7.0 billion (+31%) FY Earnings: $2.6 billion (+33%) Comments: Product sales increased 30% to a record $1.8 billion in 4Q09. Growth was driven by the company’s antiviral franchise, with strong growth in sales of Atripla and Truvada. Antiviral product sales were up 27% to $1.6 billion in the quarter. Truvada sales were $670.7 million (+19%). Viread sales were up 10% to $178.3 million. Royalty...